On 24 October 2024, the prestigious Zhangjiang CGT Summit took place at the Zhangjiang Science Hall, drawing over three hundred leading scientists, entrepreneurs, and investment experts in the field of Cell and Gene Therapy (CGT). Among the attendees, Esq. Xun Yang from Llinks Law Offices stood out as the sole legal expert, invited to present on the topic of 'Regulation and Intellectual Property in Cell Editing'.
Esq. Xun Yang commenced his presentation by outlining the critical issues surrounding ethics, human genetic resource regulation, and personal information protection in the context of in vivo, ex vivo, and pharmaceutical gene editing. He also addressed the primary considerations for mitigating and safeguarding intellectual property risks associated with the development of gene-editing technologies.
Expanding on this topic, Esq. Yang delved into pivotal intellectual property concerns within the gene-editing domain, including the origins and implications of patent disputes over gene-editing tools between academic institutions and corporate venture capital, as well as strategies for entities utilizing these technologies downstream. Furthermore, he used the example of lipid nanoparticle (LNP) targeted delivery to elucidate the key considerations for intellectual property sharing and strategy in collaborative efforts among multiple parties.
The session, led by Esq. Yang, was highly acclaimed by the attendees. With the swift progress of China's gene-editing technology and the escalating global dialogue in this domain, the legal intricacies surrounding ethics, regulatory compliance, personal data protection, intellectual property strategies, and technology transactions have become paramount concerns for companies operating in this cutting-edge sector.
